Company Filing History:
2 out of 639 
1 out of 99 
1 out of 1 Years Active: 2015-2016
Title: Greg Roth: Innovator in Cancer Treatment
Introduction
Greg Roth is an accomplished inventor based in Orlando, FL. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 2 patents, Roth's work focuses on developing methods to inhibit SUMOylation enzymes, which play a crucial role in various cellular processes.
Latest Patents
Roth's latest patents include "Singleton inhibitors of sumoylation enzymes and methods for their use." This invention provides a SUMOylation inhibitor compound that can be administered to cells to inhibit SUMOylation enzymes, specifically SUMO E1 or SUMO E2. The methods described can be utilized to treat cancer cells both in vitro and in vivo. Additionally, his patent titled "Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines" outlines methods for inhibiting small ubiquitin-like modifier enzymes, which can also be applied in cancer treatment.
Career Highlights
Throughout his career, Greg Roth has worked with notable institutions such as City of Hope and Sanford-Burnham Medical Research Institute. His research has focused on developing pharmaceutical compositions that include SUMOylation inhibitor compounds, which can be used in conjunction with DNA-damaging therapies to enhance treatment efficacy.
Collaborations
Roth has collaborated with esteemed colleagues, including Yuan Chen and Yi-Jia Li, to advance his research and contribute to the scientific community.
Conclusion
Greg Roth's innovative work in the field of cancer treatment through his patented inventions demonstrates his commitment to improving patient outcomes. His contributions to the understanding and inhibition of SUMOylation enzymes are paving the way for new therapeutic strategies.